Choose your preferred way to stay informed of new case launches and settlement deadlines
Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts." However, in a separate press release on that same day, Dyne announced that the Company's chief medical officer, chief operating officer, and chief business officer were "step[ping] down from their roles". Following this news, Dyne's stock price fell over 30% on September 3, 2024.
In order to be eligible to join the DYN class action lawsuit, you must have incurred a loss on shares of Dyne Therapeutics, Inc. purchased during the class period listed above.
TOP
